Eli Lilly and Company (TSX:LLY)
Canada flag Canada · Delayed Price · Currency is CAD
48.29
-0.38 (-0.78%)
Nov 6, 2026, 4:00 PM EST

Eli Lilly and Company Revenue

Eli Lilly and Company had revenue of $24.40B USD in the quarter ending September 30, 2026, with 38.61% growth. This brings the company's total for the last twelve months to $86.46B, up 45.51% year-over-year. In the year 2025, Eli Lilly and Company had annual revenue of $65.18B with 44.70% growth.

Revenue (ttm)
$86.46B
Revenue Growth
+45.51%
P/S Ratio
13.85
Revenue / Employee
$1.73M
Employees
50,000
Market Cap
1.70T CAD

Revenue Chart

* This company reports financials in USD.

Revenue by Segment

By Segment

Chart
  • Mounjaro 22.97B 35.2%
  • Zepbound Injectable 13.54B 20.8%
  • Oncology 9.38B 14.4%
  • Immunology 5.25B 8.1%
  • Trulicity 4.28B 6.6%
  • Jardiance 3.43B 5.3%
  • Humalog 2.17B 3.3%
  • Other 4.17B 6.4%

By Geography

Chart
  • US 43.48B 66.7%
  • Europe 11.56B 17.7%
  • Other Foreign Countries 6.06B 9.3%
  • Japan 2.13B 3.3%
  • China 1.95B 3.0%
Fiscal year ended Dec 31, 2025 See the full Eli Lilly and Company breakdown

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202565.18B20.14B44.70%
Dec 31, 202445.04B10.92B32.00%
Dec 31, 202334.12B5.58B19.56%
Dec 31, 202228.54B223.00M0.79%
Dec 31, 202128.32B3.78B15.40%
Dec 31, 202024.54B2.22B9.95%
Dec 31, 201922.32B826.20M3.84%
Dec 31, 201821.49B-1.38B-6.03%
Dec 31, 201722.87B1.65B7.77%
Dec 31, 201621.22B1.26B6.33%
Dec 31, 201519.96B343.10M1.75%
Dec 31, 201419.62B-3.50B-15.13%
Dec 31, 201323.11B509.70M2.25%
Dec 31, 201222.60B-1.68B-6.93%
Dec 31, 201124.29B1.21B5.25%
Dec 31, 201023.08B1.24B5.68%
Dec 31, 200921.84B1.46B7.19%
Dec 31, 200820.37B1.74B9.33%
Dec 31, 200718.63B2.94B18.75%
Dec 31, 200615.69B1.05B7.14%
Dec 31, 200514.65B--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.